Related references
Note: Only part of the references are listed.Novel strategy for oral peptide delivery in incretin-based diabetes treatment
Yining Xu et al.
GUT (2020)
Enterically delivered insulin tregopil exhibits rapid absorption characteristics and a pharmacodynamic effect similar to human insulin in conscious dogs
Justin M. Gregory et al.
DIABETES OBESITY & METABOLISM (2019)
Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea The PIONEER 3 Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Intestinal iontophoresis from mucoadhesive patches: a strategy for oral delivery
Amrita Banerjee et al.
JOURNAL OF CONTROLLED RELEASE (2019)
A Delivery System for Oral Administration of Proteins/Peptides Through Bile Acid Transport Channels
Siwen Wu et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
Separating host and microbiome contributions to drug pharmacokinetics and toxicity
Michael Zimmermann et al.
SCIENCE (2019)
An ingestible self-orienting system for oral delivery of macromolecules
Alex Abramson et al.
SCIENCE (2019)
Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C10)
Caroline Twarog et al.
PHARMACEUTICS (2019)
Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects
Tine A. Baekdal et al.
CLINICAL PHARMACOKINETICS (2019)
Diabetic Gastroparesis
Adil E. Bharucha et al.
ENDOCRINE REVIEWS (2019)
Oral Semaglutide vs. Empagliflozin Added On to Metformin Monotherapy in Uncontrolled Type 2 Diabetes: PIONEER 2
Eduard Montanya et al.
DIABETES (2019)
PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes
Vanita R. Aroda et al.
DIABETES CARE (2019)
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
Richard Pratley et al.
LANCET (2019)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
Ofri Mosenzon et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial
Bernard Zinman et al.
DIABETES CARE (2019)
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
Helena W. Rodbard et al.
DIABETES CARE (2019)
A luminal unfolding microneedle injector for oral delivery of macromolecules
Alex Abramson et al.
NATURE MEDICINE (2019)
Impact of Insulin Tregopil and Its Permeation Enhancer on Pharmacokinetics of Metformin in Healthy Volunteers: Randomized, Open-Label, Placebo-Controlled, Crossover Study
Anand Khedkar et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2019)
Long-term oral administration of Exendin-4 to control type 2 diabetes in a rat model
Kenichi Suzuki et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Synthesis of CSK-DEX-PLGA Nanoparticles for the Oral Delivery of Exenatide to Improve Its Mucus Penetration and Intestinal Absorption
Yina Song et al.
MOLECULAR PHARMACEUTICS (2019)
Non-invasive delivery strategies for biologics
Aaron C. Anselmo et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
THE ACTIVITY OF PEPTIDES OF THE CALCITONIN FAMILY IN BONE
Dorit Naot et al.
PHYSIOLOGICAL REVIEWS (2019)
Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial
Inge B. Halberg et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Jejunal wall delivery of insulin via an ingestible capsule in anesthetized swine-A pharmacokinetic and pharmacodynamic study
Mir Hashim et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2019)
Enhanced oral absorption of insulin using colon-specific nanoparticles co-modified with amphiphilic chitosan derivatives and cell-penetrating peptides
Feng Guo et al.
BIOMATERIALS SCIENCE (2019)
Oral insulin delivery: existing barriers and current counter-strategies
Ahmed Gedawy et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2018)
Cell-Cell Junctions Organize Structural and Signaling Networks
Miguel A. Garcia et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2018)
Combination Strategy with Complexation Hydrogels and Cell-Penetrating Peptides for Oral Delivery of Insulin
Yu Fukuoka et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2018)
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment
Charlotte Granhall et al.
CLINICAL PHARMACOKINETICS (2018)
Multiple Oral Insulin (ORMD-0801) Doses Elicit a Cumulative Effect on Glucose Control in T2DM Patients
Roy Eldor et al.
DIABETES (2018)
Insulin Access and Affordability Working Group: Conclusions and Recommendations
William T. Cefalu et al.
DIABETES CARE (2018)
Microparticles, microcapsules and microspheres: A review of recent developments and prospects for oral delivery of insulin
Chun Y. Wong et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2018)
The use of low molecular weight protamine to enhance oral absorption of exenatide
Liping Zhang et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2018)
Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment
Tine A. Baekdal et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Increased jejunal permeability in human obesity is revealed by a lipid challenge and is linked to inflammation and type 2 diabetes
Laurent Genser et al.
JOURNAL OF PATHOLOGY (2018)
Oral delivery of anti-diabetes therapeutics using cell penetrating and transcytosing peptide strategies
Sahrish Rehmani et al.
PEPTIDES (2018)
Ionic liquids for oral insulin delivery
Amrita Banerjee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection
Christoph A. Thaiss et al.
SCIENCE (2018)
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
Richard E. Pratley et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Multifunctional Nanoparticles Enable Efficient Oral Delivery of Biomacromolecules via Improving Payload Stability and Regulating the Transcytosis Pathway
Yaxian Zheng et al.
ACS APPLIED MATERIALS & INTERFACES (2018)
Oral peptide delivery: Translational challenges due to physiological effects
Puneet Tyagi et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist
Stephen T. Buckley et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Bioprinted 3D Primary Human Intestinal Tissues Model Aspects of Native Physiology and ADME/Tox Functions
Lauran R. Madden et al.
ISCIENCE (2018)
Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes A Randomized Clinical Trial
Melanie Davies et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Discovery, characterization, and clinical development of the glucagon-like peptides
Daniel J. Drucker et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Rational design of polyarginine nanocapsules intended to help peptides overcoming intestinal barriers
Zhigao Niu et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Safety and efficacy of self-assembling bubble carriers stabilized with sodium dodecyl sulfate for oral delivery of therapeutic proteins
Po-Yen Lin et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Orally Absorbed Cyclic Peptides
Daniel S. Nielsen et al.
CHEMICAL REVIEWS (2017)
Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5
John B. Buse et al.
DIABETES CARE (2016)
Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials
T. A. S. Aguirre et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
Intestinal permeation enhancers for oral peptide delivery
Sam Maher et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
Oral absorption of peptides and nanoparticles across the human intestine: Opportunities, limitations and studies in human tissues
P. Lundquist et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D
Kim Henriksen et al.
BONE (2016)
Lysosomal solute carrier transporters gain momentum in research
B. Bissa et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
Self-reported Barriers to Adherence and Persistence to Treatment With Injectable Medications for Type 2 Diabetes
C. Victor Spain et al.
CLINICAL THERAPEUTICS (2016)
Enhancement of oral insulin bioavailability: in vitro and in vivo assessment of nanoporous stimuli-responsive hydrogel microparticles
Naveed Ahmad et al.
EXPERT OPINION ON DRUG DELIVERY (2016)
Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis
Leonardo Bandeira et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
Preparation and in vivo evaluation of an orally available enteric-microencapsulated parathyroid hormone (1-34)-deoxycholic acid nanocomplex
Seung Rim Hwang et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2016)
Enhancing insulin oral absorption by using mucoadhesive nanoparticles loaded with LMWP-linked insulin conjugates
Jianyong Sheng et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Safety concerns over the use of intestinal permeation enhancers: A mini-review
Fiona McCartney et al.
TISSUE BARRIERS (2016)
Overcoming the Diffusion Barrier of Mucus and Absorption Barrier of Epithelium by Self-Assembled Nanoparticles for Oral Delivery of Insulin
Wei Shan et al.
ACS NANO (2015)
Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial
Juris J. Meier et al.
DIABETES CARE (2015)
Upper gastrointestinal motility and symptoms in individuals with diabetes, prediabetes and normal glucose tolerance
Georgios C. Boronikolos et al.
DIABETOLOGIA (2015)
Effective incorporation of insulin in mucus permeating self-nanoemulsifying drug delivery systems
Theodora Karamanidou et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2015)
Steric and interactive barrier properties of intestinal mucus elucidated by particle diffusion and peptide permeation
Marie Boegh et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2015)
Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial
Shlomo Melmed et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Semaglutide, a Once-Weekly Human GLP-1 Analog, Does Not Reduce the Bioavailability of the Combined Oral Contraceptive, Ethinylestradiol/Levonorgestrel
Christoph Kapitza et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Improved oral absorption of exenatide using an original nanoencapsulation and microencapsulation approach
Liat Soudry-Kochavi et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Intestinal and hepatic drug transporters: pharmacokinetic, pathophysiological, and pharmacogenetic roles
Tomohiro Terada et al.
JOURNAL OF GASTROENTEROLOGY (2015)
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
Jesper Lau et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Analysis of Intra- and lntersubject Variability in Oral Drug Absorption in Human Bioequivalence Studies of 113 Generic Products
Masahisa Sugihara et al.
MOLECULAR PHARMACEUTICS (2015)
Toward Oral Delivery of Biopharmaceuticals: An Assessment of the Gastrointestinal Stability of 17 Peptide Drugs
Jie Wang et al.
MOLECULAR PHARMACEUTICS (2015)
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Xavier Pi-Sunyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Strategic Approaches to Optimizing Peptide ADME Properties
Li Di
AAPS JOURNAL (2015)
Mucus as a Barrier to Drug Delivery - Understanding and Mimicking the Barrier Properties
Marie Boegh et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2015)
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Bradley Croy Doak et al.
CHEMISTRY & BIOLOGY (2014)
Diabetes Insipidus: Celebrating a Century of Vasopressin Therapy
Sana Qureshi et al.
ENDOCRINOLOGY (2014)
A Novel Suspension Formulation Enhances Intestinal Absorption of Macromolecules Via Transient and Reversible Transport Mechanisms
Shmuel Tuvia et al.
PHARMACEUTICAL RESEARCH (2014)
Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH2] in postmenopausal women with osteoporosis
K. Henriksen et al.
BONE (2013)
Pharmacokinetics of Oral Recombinant Human Parathyroid Hormone [rhPTH(1-31)NH2] in Postmenopausal Women with Osteoporosis
Amy Sturmer et al.
CLINICAL PHARMACOKINETICS (2013)
Paracellular drug absorption enhancement through tight junction modulation
Hendrik J. R. Lemmer et al.
EXPERT OPINION ON DRUG DELIVERY (2013)
Mucoadhesive intestinal devices for oral delivery of salmon calcitonin
Vivek Gupta et al.
JOURNAL OF CONTROLLED RELEASE (2013)
Human colonic mucus is a reservoir for antimicrobial peptides
Lena Antoni et al.
Journal of Crohns & Colitis (2013)
The gastrointestinal mucus system in health and disease
Malin E. V. Johansson et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2013)
Glucose-Reducing Effect of the ORMD-0801 Oral Insulin Preparation in Patients with Uncontrolled Type 1 Diabetes: A Pilot Study
Roy Eldor et al.
PLOS ONE (2013)
Mucus Enhances Gut Homeostasis and Oral Tolerance by Delivering Immunoregulatory Signals
Meimei Shan et al.
SCIENCE (2013)
Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study
Michael Mannstadt et al.
LANCET DIABETES & ENDOCRINOLOGY (2013)
Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers
Laura M. Ensign et al.
ADVANCED DRUG DELIVERY REVIEWS (2012)
The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women
Sibylle P. Haemmerle et al.
BONE (2012)
Metabolism and disposition of the oral absorption enhancer 14C-radiolabeled 8-(N-2-hydroxy-5-chlorobenzoyl)-amino-caprylic acid (5-CNAC) in healthy postmenopausal women and supplementary investigations in vitro
Hans-Peter Gschwind et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: The oral calcitonin in postmenopausal osteoporosis (ORACAL) trial
Neil Binkley et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Oral Octreotide Absorption in Human Subjects: Comparable Pharmacokinetics to Parenteral Octreotide and Effective Growth Hormone Suppression
S. Tuvia et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Zonula occludens-1 and-2 regulate apical cell structure and the zonula adherens cytoskeleton in polarized epithelia
Alan S. Fanning et al.
MOLECULAR BIOLOGY OF THE CELL (2012)
A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects
A. Khedkar et al.
DIABETES OBESITY & METABOLISM (2010)
Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein
Wolfgang Glaesner et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2010)
Liraglutide
Daniel J. Drucker et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Intestinal barrier function: Molecular regulation and disease pathogenesis
Katherine R. Groschwitz et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)
Complexation hydrogels for intestinal delivery of interferon β and calcitonin
Noriyasu Kamei et al.
JOURNAL OF CONTROLLED RELEASE (2009)
Discovery of synergistic permeation enhancers for oral drug delivery
Kathryn Whitehead et al.
JOURNAL OF CONTROLLED RELEASE (2008)
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Daniel J. Drucker et al.
LANCET (2008)
Mechanistic analysis of chemical permeation enhancers for oral drug delivery
Kathryn Whitehead et al.
PHARMACEUTICAL RESEARCH (2008)
Safe and effective permeation enhancers for oral drug delivery
Kathryn Whitehead et al.
PHARMACEUTICAL RESEARCH (2008)
Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use
AB Hodsman et al.
ENDOCRINE REVIEWS (2005)
A novel per-oral insulin formulation: proof of concept study in non-diabetic subjects
M Kidron et al.
DIABETIC MEDICINE (2004)
Increased iNOS activity is essential for intestinal epithelial tight junction dysfunction in endotoxemic mice
XN Han et al.
SHOCK (2004)
Potential utility of various protease inhibitors for improving the intestinal absorption of insulin in rats
H Liu et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2003)
Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers
T Buclin et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2002)
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study
CH Chesnut et al.
AMERICAN JOURNAL OF MEDICINE (2000)
Share Paper
